This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Impact · against what's priced in

Viridian Therapeutics faces a binary valuation event with a June 30 PDUFA date and upcoming Phase 3 readouts. While institutional trimming by Kynam Capital suggests a cautious approach following a stock run, the company's strong cash position of $875 million provides a sufficient buffer against its current burn rate.

VRDN−0.10: No priced-in read yet

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

What matters in this story

Aura Biosciences: A Pivotal Trial Engineered With Room To Spare

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

What matters in this story

Aura Biosciences: A Pivotal Trial Engineered With Room To Spare

How each ticker is affected

Track these names every morning.

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk

ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Anthropic's IPO push includes a big bet on life sciences

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

What matters in this story

Next reads from the same story arc

Aura Biosciences: A Pivotal Trial Engineered With Room To Spare

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

What matters in this story

Next reads from the same story arc

Aura Biosciences: A Pivotal Trial Engineered With Room To Spare

How each ticker is affected

Track these names every morning.

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk

ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Anthropic's IPO push includes a big bet on life sciences